Equities

Fibrobiologics Inc

Fibrobiologics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.86
  • Today's Change0.36 / 8.00%
  • Shares traded81.50k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jul 22 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

FibroBiologics Inc is a United States-based company. The Company operates as a biopharmaceutical company. It is focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. It also develops biologic cures and treatments for chronic diseases, including degenerative disc disease, multiple sclerosis, wound healing, and cancer, and anti-aging extension of life applications such as thymic involution reversal and splenic involution reversal.

  • Revenue in USD (TTM)0.00
  • Net income in USD-22.53m
  • Incorporated2021
  • Employees10.00
  • Location
    Fibrobiologics Inc455 E. Medical Center Blvd, Suite 300HOUSTON 77598United StatesUSA
  • Phone+1 (281) 671-5150
  • Fax+1 (302) 655-5049
  • Websitehttps://fibrobiologics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Fennec Pharmaceuticals Inc44.95m2.84m181.70m36.00181.8459.8063.894.040.03660.03661.620.11120.98781.157.52--6.25-73.437.37-84.3296.19--6.33-383.286.721.840.9087--1,284.50--32.34------
Rigel Pharmaceuticals Inc120.35m-19.80m181.73m147.00------1.51-1.13-1.136.90-1.810.96230.92414.23818,680.30-15.83-28.82-30.14-47.2693.2297.88-16.45-35.761.17-2.912.13---2.7921.3057.16--68.45--
Adverum Biotechnologies Inc0.00-112.90m182.25m121.00--0.9997-----10.23-10.230.008.780.00----0.00-41.55-36.39-47.50-39.04-------5,279.60----0.00----17.4324.18---0.0247--
G1 Therapeutics Inc84.04m-30.59m184.03m100.00--6.63--2.19-0.6146-0.61461.550.5310.63670.48526.07840,410.00-23.18-47.06-30.95-52.6491.89---36.40-268.592.55-3.310.6084--60.84--67.49------
Acumen Pharmaceuticals Inc0.00-55.94m184.44m51.00--0.7039-----1.05-1.050.004.360.00----0.00-22.89---23.72--------------0.1034-------22.20------
Rani Therapeutics Holdings Inc0.00-33.08m186.56m140.00--24.12-----1.29-1.290.000.15340.00----0.00-87.80---140.92-------------28.750.6695-------11.06------
Biomea Fusion Inc0.00-127.27m191.23m110.00--1.41-----3.57-3.570.003.770.00----0.00-90.54---107.35--------------0.00-------43.29------
Fibrobiologics Inc0.00-22.53m192.53m10.00---------1.03-1.030.00-0.1181------0.00-----------------------------272.15------
Pyxis Oncology Inc16.15m-57.80m192.57m51.00--1.04--11.93-1.39-1.390.3683.130.0801----322,920.00-28.68---30.64--97.06---358.00------0.00------38.87------
Metagenomi Inc-100.00bn-100.00bn194.06m237.00--0.7041----------7.36----------------------------0.00--160.21---56.57------
Candel Therapeutics Inc0.00-37.37m195.50m42.00--32.25-----1.29-1.290.000.20370.00----0.00-75.90---93.79-------------38.490.7674---100.00---101.87------
Coherus Biosciences Inc301.87m-59.29m199.62m249.00------0.6613-0.7801-0.78012.86-0.72110.51783.171.71986,506.60-10.17-21.43-23.51-29.3241.4679.01-19.64-36.561.05-3.871.21--21.89--18.46---18.37--
Trevi Therapeutics Inc0.00-33.57m200.04m25.00--2.71-----0.338-0.3380.001.050.00----0.00-34.47-47.39-38.08-54.41------------0.0017------0.2984---2.81--
Lineage Cell Therapeutics Inc8.00m-23.66m200.15m75.00--2.76--25.01-0.1344-0.13440.04550.38360.0722--57.16106,706.70-21.32-19.53-24.82-22.5991.8889.13-295.30-370.88----0.0018---39.1612.3918.22---27.16--
XBiotech Inc0.00-30.74m200.41m92.00--0.9574-----1.01-1.010.006.870.00----0.00-13.0831.88-13.6833.27------877.30----0.04560.00-100.00--25.36--24.30--
Generation Bio Co9.96m-169.06m202.25m174.00--1.53--20.30-2.56-2.560.15091.990.0278--10.9857,258.62-47.14-36.96-50.75-39.21-----1,696.87-8,879.44----0.00----177.317.34--19.61--
Data as of Jul 22 2024. Currency figures normalised to Fibrobiologics Inc's reporting currency: US Dollar USD

Institutional shareholders

1.91%Per cent of shares held by top holders
HolderShares% Held
Millennium Management LLCas of 31 Mar 2024209.23k0.64%
Transform Wealth LLCas of 30 Jun 2024133.89k0.41%
HRT Financial LLCas of 31 Mar 202457.34k0.18%
Marshall Wace LLPas of 31 Mar 202452.03k0.16%
State Street Global Advisors Trust Co.as of 04 Jul 202440.00k0.12%
ERn Financial LLCas of 30 Jun 202431.82k0.10%
Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 202430.42k0.09%
ExodusPoint Capital Management LPas of 31 Mar 202425.59k0.08%
JPMorgan Securities LLC (Investment Management)as of 31 Mar 202422.63k0.07%
Saxon Interests, Inc.as of 30 Jun 202421.21k0.07%
More ▼
Data from 31 Mar 2024 - 18 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.